The onset of amyotrophic lateral sclerosis

de Carvalho, M.; Swash, M.
March 2006
Journal of Neurology, Neurosurgery & Psychiatry;Mar2006, Vol. 77 Issue 3, p388
Academic Journal
Two patients in whom both the neurological examination and electromyography (EMG) were normal prior to the onset of amyotrophic lateral sclerosis (ALS) are reported. In each patient, the onset of ALS some 18 months later was clearly defined clinically and confirmed by subsequent EMG studies. These unique observations show that ALS commences at a defined time, and that there is early generalisation with an initial phase of rapid progression.


Related Articles

  • Detecting fasciculations in amyotrophic lateral sclerosis: duration of observation required. Mills, Kerry R. // Journal of Neurology, Neurosurgery & Psychiatry;May2011, Vol. 82 Issue 5, p549 

    A practical issue in the diagnosis of amyotrophic lateral sclerosis (ALS) is how long the EMG must be observed before a muscle can be declared free of fasciculations with some degree of certainty. To answer this question, the intervals between fasciculation potentials (FPs) were recorded from 53...

  • Locked-in: don't judge a book by its cover. Bruno, M.; Bernheim, J. L.; Schnakers, C.; Laureys, S. // Journal of Neurology, Neurosurgery & Psychiatry;Jan2008, Vol. 79 Issue 1, p2 

    The article presents the author's views regarding the amyotrophic lateral sclerosis (ALS), a devastating medical condition that progressively robs patients of their ability to move, speak, and eventually breathe, in Great Britain. In accordance with the principle of patient autonomy, physicians...

  • TARDBP gene mutations in south Italian patients with amyotrophic lateral sclerosis. Conforti, F. L.; Sproviero, W.; Simone, I. L.; Mazzei, R.; Valentino, P.; Ungaro, C.; Magariello, A.; Patitucci, A.; La Bella, V.; Sprovieri, T.; Tedeschi, G.; Citrigno, L.; Gabriele, A. L.; Bono, F.; Monsurrò, M. R.; Muglia, M.; Gambardella, A.; Quattrone, A. // Journal of Neurology, Neurosurgery & Psychiatry;May2011, Vol. 82 Issue 5, p587 

    The article examines cases of TAR-deoxyribonucleic acid-binding protein (TARDBP) gene mutations in patients with amyotrophic lateral sclerosis (ALS) from south Italy. According to the author, TAR-DNA-binding protein 43 (TDP-43) has been identified as the primary pathological protein in abnormal...

  • Amyotrophic lateral sclerosis diagnosis overturned. Gorelov, Dmitri; Respicio, Guada // Cortlandt Forum;May2007, Vol. 20 Issue 5, p50 

    The article presents a case analysis of spinal dural fistula which was misdiagnosed as amyotrophic lateral sclerosis (ALS). The subacute progression of weakness in the lower extremities of a 61-year-old man, the presence of both upper and lower motor-neuron signs and the electromyography...

  • α-Synuclein-immunoreactive structure formation is enhanced in sympathetic ganglia of patients with multiple system atrophy. Sone, Mie; Yoshida, Mari; Hashizume, Yoshio; Hishikawa, Nozomi; Sobue, Gen // Acta Neuropathologica;Jul2005, Vol. 110 Issue 1, p19 

    We immunohistochemically examined the sympathetic ganglia (SG) and brains of 26 patients with multiple system atrophy (MSA), 19 age-matched controls, and 25 patients with amyotrophic lateral sclerosis (ALS). α-Synuclein-immunoreactive structures were found in the neuronal cytoplasm and...

  • Motor neurone disease: an overview. Kent, Anna // Nursing Standard;7/18/2012, Vol. 26 Issue 46, p48 

    Motor neurone disease (MND) is a relatively rare, progressive and incurable neurological condition affecting patients' speech, mobility and respiratory function. Care of patients with MND is complex and involves various healthcare professionals and services. There is a need to discuss symptom...

  • Rash in a patient with primary lateral sclerosis. Singer, Karl; Georgi, Kristen // Patient Care;May2004, Vol. 38 Issue 5, p52 

    Presents a medical case of a skin rash in a patient with primary lateral sclerosis. Medical history of the patient; Medications given to the patient; Description of the disease.

  • Minocycline in amyotrophic lateral sclerosis: a pilot study. Pontieri, F. E.; Ricci, A.; Pellicano, C.; Benincasa, D.; Buttarelli, F. R. // Neurological Sciences;Oct2005, Vol. 26 Issue 4, p285 

    Recent studies indicate that minocycline exerts neuroprotective effects in vitro and in vivo, and suggest that the drug may represent a novel therapeutic approach to amyotrophic lateral sclerosis (ALS). In this study we investigated the safety of combined treatment with minocycline and riluzole...

  • An Association Study of Riluzole Serum Concentration and Survival and Disease Progression in Patients With ALS. Groeneveld, G. J.; van Kan, H. J. M.; Lie-A-Huen, L.; Guchelaar, H.-J.; van den Berg, L. H. // Clinical Pharmacology & Therapeutics;May2008, Vol. 83 Issue 5, p718 

    Patients with amyotrophic lateral sclerosis (ALS) who are treated with the antiglutamatergic drug riluzole receive a fixed-dose regimen of 50 mg b.i.d. The drug has been shown to increase tracheostomy-free survival by 3–6 months. The pharmacokinetics of riluzole show a high...


Read the Article


Sign out of this library

Other Topics